BOULEVARD-BP30099: A multiple-center, multiple-dose, randomized, active comparator−controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of ro6867461 administered intravitreally in patients with Diabetic Macular Edema

LADDER-GX28228: A phase II, multicenter, randomized, active treatment−controlled study of the efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with subfoveal Neovascular Age-Related Macular Degeneration

OMASPECT-GX30191: A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with geographic atrophy secondary to Age-Related Macular Degeneration who have completed a Roche-sponsored study

SPECTRI-GX29185: A Phase III, Multicenter, Randomized, Double-Masked, Sham - Controlled Study To Assess The Efficacy And Safety of Lampalizumab Administered Intravitreally To Patients with Geographic Atrophy Secondary To Age-Related Macular Degeneration

PROXIMA A- GX 29633: A multicenter, prospective epidemiologic study of the progression of Geographic Atrophy secondary to Age−Related Macular Degeneration

TREX DME- A phase I/II, open-label, multicenter, randomized, controlled study of the safety, tolerability and efficacy of intravitreal injections of 0.3 milligram Ranibizumab given monthly compared to a TReat and EXtend protocol, with and without laser photocoagulation, in patients with Diabetic Macular Edema